Scanning for Plaques: A New Frontier in
Alzheimer’s Disease
Newswise, March 11, 2012 — When 225
researchers from around the world convened
in Miami to exchange the latest on β amyloid
positron emission tomography in January,
there was a palpable sense of urgency.
At the 6th Annual Human Amyloid Imaging
(HAI) Conference, the possibility of
approval, potentially within months, of the
first amyloid-scanning compound for clinical
use hung over the room.
As scientists openly discussed new research
developments on all fronts of this young
field, they also wrestled with whether and
how to disclose plaque status to people
without dementia, how to use amyloid scans
in the clinic, and how to reliably read
plaque scans.
Scientists presented new data on how genes
and age influence plaque deposition, as they
start to pinpoint when and where this
pathology first crops up in the brain.
A growing number of longitudinal studies
that follow cognitively normal and mildly
impaired people at varying degrees of
genetic risk suggest brain amyloid
deposition is bad news, though it often
takes years before someone shows symptoms of
forgetfulness.
But even as longitudinal studies converge,
all does not fit. The conference brought to
a boil a theme that has been simmering: In
many cases, plaque scans don’t match a
patient’s clinical Alzheimer’s diagnosis,
and more research is needed to find out
which of the two is more accurate.
This process may shake up the diagnosis of
AD and give more prominence to related,
understudied forms of dementia.
At the conference, researchers agreed that
the field urgently needs compounds to trace
all defining pathologies, above all,
neurofibrillary tangles.
The debut of the first tau-only scan data in
humans received rapt attention, and two more
compounds are in late preclinical stages. A
nine-part series
http://www.alzforum.org/new/detail.asp?id=3074
by Alzforum reporters covers these points
and more.